Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

ENDRA Life Sciences (NDRA) Receivables - Net (2017 - 2018)

ENDRA Life Sciences has reported Receivables - Net over the past 2 years, most recently at $12275.0 for Q3 2018.

  • Quarterly Receivables - Net changed N/A to $12275.0 in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $12275.0 through Sep 2018, changed N/A year-over-year, with the annual reading at $6850.0 for FY2017, N/A changed from the prior year.
  • Receivables - Net was $12275.0 for Q3 2018 at ENDRA Life Sciences, up from $11770.0 in the prior quarter.
  • Over five years, Receivables - Net peaked at $12275.0 in Q3 2018 and troughed at $6850.0 in Q4 2017.